US National Library of MedicineNational Institutes of Health

Search database
Pediatr Dermatol. 2009 May-Jun;26(3):262-8. doi: 10.1111/j.1525-1470.2008.00856.x.

Fluocinolone acetonide 0.01% in peanut oil: safety and

efficacy data in the treatment of childhood atopic
dermatitis in infants as young as 3 months of age.
Dohil MA1, Alvarez-Connelly E, Eichenfield LF.

Author information
Months of Age Fluocinolone Acetonide 0.01% in Peanut
Oil: Safety and Efficacy Data in the Treatment of
Childhood Atopic Dermatitis in Infants as Young as 3
Magdalene A. Dohil M.D.

Elizabeth Alvarez‐Connelly M.D.

Lawrence F. Eichenfield M.D.
First published: 10 June 2009
https://doi.org/10.1111/j.1525-1470.2008.00856.x

Cited by: 6

Address correspondence to Magdalene A. Dohil, M.D., Pediatric Dermatology; Rady

Children's Hospital, 8010 Frost Street, #602, San Diego, CA USA 92123 or e‐
mail: mdohil@rchsd.org.
Read the full text

PDF
TOOLS

SHARE

Abstract
 Abstract: weeks of twice daily treatment. months of age
with atopic dermatitis. No evidence of adrenal suppression or
adverse local effects was demonstrated after 4 weeks.
Cortisol stimulation testing was performed at baseline and at
the end of the treatment phase. Patients were monitored for
medication use and adverse events. Efficacy was assessed
using the Investigator Global Severity and Response scales.
Thirty‐two patients with moderate to severe atopic dermatitis
were recruited into the study and 30 were evaluated with the
Physician’s Global Improvement Assessment tool. The mean
body surface ratio treated for all age groups was 48%. Eighty‐
three percent of patients had marked or better improvement
scores by week 2 and 96% by week 4, with 40% completely
cleared. No adrenal suppression occurred in the 24 patients
that met inclusion criteria for hypothalamus‐pituitary axis (HPA)
axis analysis. No relevant adverse events occurred. Results of
this study support the safety and efficacy of fluocinolone
acetonide 0.01% in refined peanut oil vehicle, for infants as
young as 3 years with moderate to severe atopic dermatitis at
two academic pediatric dermatology centers. Patients received
topical fluocinolone acetonide 0.01% oil twice daily to affected
areas involving a minimum of 20% body surface ratio for 4 
months to 2 months of age. A controlled, open‐label study
was performed in children aged 3 years and older, including
those with peanut sensitivity, for several years. We sought to
study the safety of fluocinolone acetonide 0.01% oil and its
potential for adrenal axis suppression in infants as young as
3 Fluocinolone acetonide 0.01% in a blend of refined peanut
and mineral oils has been established as effective and safe
treatment for atopic dermatitis in patients 2